NCT06416410 2025-04-04JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationAllist Pharmaceuticals, Inc.Phase 3 Recruiting392 enrolled